性别对成人急性髓系白血病治疗结局的预后影响
该研究纳入1984年至2008年10项多中心治疗研究中的3546例新诊断急性髓系白血病患者(含548例急性早幼粒细胞白血病),采用Kaplan-Meier和多因素模型分析性别对生存的影响。非APL女性患者总生存显著优于男性,但与年龄、初始白细胞计数或柔红霉素剂量无关;APL女性患者的总生存和无病生存均显著优于男性。性别是AML的独立预后变量。
要点
- 非APL女性AML患者总生存优于男性,无病生存无差异。
- APL女性患者总生存和无病生存均显著优于男性。
- 性别是AML的独立预后变量,机制尚不明确。
核心结论
- 性别是成人AML患者的独立预后变量,女性在非APL和APL中均显示生存优势。
主要发现
- 非APL女性患者总生存显著优于男性,无病生存无显著差异,且不受年龄、初始白细胞计数或柔红霉素剂量影响。
- 肥胖或FLT3-ITD阳性患者中未观察到性别生存差异。
- APL女性患者总生存和无病生存均显著优于男性,且t(15;17)合并其他细胞遗传学异常者的生存差异更大。
临床怎么用
- 性别可作为AML预后评估的参考因素,但需结合细胞遗传学和分子特征综合判断。
局限性
- 生存差异的机制(激素、遗传、药代动力学或吸烟等暴露)尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are conflicting reports in the literature suggesting that one gender or the other has a better survival with acute myeloid leukaemia (AML). The present study was done in an attempt to resolve the issue. The effect of gender was examined on 3546 newly diagnosed patients with AML, including 548 patients with acute promyelocytic leukaemia (APL) enrolled in 10 multi-institutional treatment studies from March 1984 to November 2008. Kaplan-Meier estimates were used to estimate event-time distributions for survival and multivariate models were used to examine the gender effect after adjusting for multiple risk factors. P values were based on two-sided tests. Non-APL female patients had a significantly better overall (OS) but not disease-free survival (DFS) than males, irrespective of age, initial white blood cell count, or dose of daunorubicin. No differences were observed for obese or FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive patients. Female patients with APL had a significantly better OS and DFS than male patients with APL, and differences in survival were greater for patients with t(15;17) + other cytogenetic abnormalities compared with those with t(15;17) only. Gender is an independent prognostic variable in patients with AML. Whether these survival differences are due to hormonal, genetic or pharmacokinetic differences between the sexes or differential toxin exposure such as smoking is unknown. However, the former seems less likely as patient age did not influence the survival advantage for female patients.
引用
- Wiernik PH, Sun Z, Cripe LD, et al. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. Br J Haematol. 2021. PMID: 34145576. doi:10.1111/bjh.17523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。